EP1141372A2 - Production in vivo amelioree de cephalosporines - Google Patents

Production in vivo amelioree de cephalosporines

Info

Publication number
EP1141372A2
EP1141372A2 EP99964657A EP99964657A EP1141372A2 EP 1141372 A2 EP1141372 A2 EP 1141372A2 EP 99964657 A EP99964657 A EP 99964657A EP 99964657 A EP99964657 A EP 99964657A EP 1141372 A2 EP1141372 A2 EP 1141372A2
Authority
EP
European Patent Office
Prior art keywords
aca
side chain
acetyltransferase
chrysogenum
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99964657A
Other languages
German (de)
English (en)
Inventor
Roelof Ary Lans Bovenberg
Richard Kerkman
Eric Koenhen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM BV
Original Assignee
DSM NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM NV filed Critical DSM NV
Priority to EP99964657A priority Critical patent/EP1141372A2/fr
Publication of EP1141372A2 publication Critical patent/EP1141372A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P35/00—Preparation of compounds having a 5-thia-1-azabicyclo [4.2.0] octane ring system, e.g. cephalosporin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)

Definitions

  • the present invention relates to a process for the production of cephalosporins and in particular for the production of 7-ACA or a derivative thereof comprising the steps of fermenting a P. chrysogenum strain being transformed with an expression construct comprising a nucleotide sequence encoding an expandase, a hydroxylase and an acetyltransferase in the presence of a suitable acyl side chain precursor, or a salt or ester thereof, such that an N-acylated 7-ACA compound is produced, N-deacylating the thus produced N-acylated 7-ACA compound and, optionally, acylating the free amino group and/or substituting the 3' acetate group with a side chain suitable to form a cephalosporin antibiotic .
  • cephalosporins Semi-synthetic routes to prepare cephalosporins mostly start from fermentation products such as penicillin G, penicillin V and cephalosporin C, which are converted to the corresponding ⁇ -lactam nuclei, for instance in a manner as is disclosed in K. Matsumoto, Bioprocess. Techn., 16, , 67-88 (1 993), J.G. Shewale & H. Sivaraman, Process Biochemistry, August 1 989, 1 46-1 54, T.A. Savidge, Biotechnology of Industrial Antibiotics (Ed. E.J. Vandamme) Marcel Dekker, New York, 1 984, or J.G. Shewale et al., Process Biochemistry International, June 1 990, 97-103.
  • the obtained ⁇ -lactam nuclei are subsequently converted to the desired antibiotic by coupling to a suitable side chain, as has been described in inter alia EP 0 339 751 , JP 530051 85 and CH 640 240.
  • a suitable side chain as has been described in inter alia EP 0 339 751 , JP 530051 85 and CH 640 240.
  • cephalosporin nuclei 7-amino desacetoxycephalosporanic acid (7- ADCA) and 7-amino cephalosporanic acid (7-ACA) are known to be the most important intermediates for the production of antibiotics used in the pharmaceutical industry.
  • Cephalosporin C is by far the most important starting material for preparation of 7-ACA as well as for other therapeutically used cephalosporins.
  • cephalosporin C is very soluble in water at any pH, and this implies lengthy and costly isolation processes using cumbersome and expensive column technology to remove non-converted cephalosporin C from its product.
  • the ⁇ -aminoadipoyl side chain of cephalosporin C is not very amenable to the enzymatical or chemical cleavage necessary to produce 7-ACA.
  • adipoyl-7-ACA adipoyl-7-amino desacetylcephalosporanic acid
  • adipoyl-7-ADAC adipoyl-7-amino desacetylcephalosporanic acid
  • the present invention discloses acetyltransferase expression constructs which are designed such as to obtain a high expression level of acetyltransferase. In this way, an increased amount of the precursor adipoyl- 7-ADAC is converted to adipoyl-7-ACA.
  • the documents describing the cloning and nucleotide sequence of the acetyltransferase gene from Acremonium chrysogenum (cefG) disclose a coding sequence starting either at the first (EP 0 437 378; Gutierrez et al, , J. Bacteriol. 174: 3056-3064 (1 992)), the second (Mathison et al. , Curr Genet.
  • the present invention discloses a process for the production of 7-ACA or a derivative thereof comprising the steps of fermenting a P. chrysogenum strain being transformed with an expression construct comprising a nucleotide sequence encoding expandase, hydroxylase and acetyltransferase activity in the presence of a suitable acyl side chain precursor, or a salt or ester thereof, such that an N-acylated 7-ACA compound is produced, N-deacylating the thus produced N-acylated 7-ACA compound and, optionally, acylating the free amino group and/or substituting the 3' acetate group with a side chain suitable to form a cephalosporin antibiotic, characterised in that the nucleotide sequence encoding the acetyltransferase is derived from A. chrysogenum and starts at the second ATG of said nucleotide sequence.
  • an expression construct comprising the acetyltransferase coding sequence from A. chrysogenum is expressed more efficiently when the coding sequence starts at the second ATG of the open reading frame (ORF) than when it starts at the first or the third ATG of said ORF.
  • ORF open reading frame
  • One of the effects of a more efficient acetyltransferase expression is that the N-acylated 7-ADAC derivative is converted more efficiently to the N-acylated 7-ACA derivative.
  • a transformed P. chrysogenum strain is used expressing the three enzymatic activities of the cephalosporin biosynthetic pathway leading to the production of a 3'-acetylated cephalosporin compound.
  • Suitable sources for the genes encoding said three enzymatic activities are the bacteria Streptomyces clavuligerus or Nocardia lactamdurans for the expandase gene cefE and the hydroxylase gene cefF (see EP 0 341 892 for cefE and EP 0 465 1 89 for cefF) or the fungus A. chrysogenum for the bifunctional expandase / hydroxylase gene cefEF and the acetyltransferase gene cefG (see EP 0 281 391 and Coque et al. , Mol. Gen. Genet.
  • the acetyltransferase enzyme activity is provided by the cefG gene as obtained from A. chrysogenum.
  • the present invention shows that it is advantageous to use the second ATG of the cefG ORF as the start codon.
  • the use of the second ATG of the cefG ORF as the start codon implicates that the acetyltransferase enzyme as used in the process of the present invention has an N-terminal amino acid sequence starting with methionine-leucine-arginine-aspartic acid- serine.
  • the genes encoding the three enzymatic activities expandase, hydroxylase and acetyltransferase may be provided with 5' and 3' regulatory sequences native to the genes in question or may be provided with regulatory sequences heterologous to said genes.
  • suitable 5' and 3' regulatory sequences i.e. promoters and terminators, providing for recombinant gene expression in filamentous fungus host cells are mentioned in Van den Hondel et al. (in: More Gene Manipulations in Fungi, Eds. Bennett and Lasure , 396-427 (1991 )) or in Applied Molecular Genetics of filamentous fungi (Kinghorn, Turner (eds.), Blackie, Glasgow, UK, 1 992) .
  • Preferred promoters are the Aspergillus niger glucoamylase promoter or P.
  • chrysogenum promoters derived from the genes encoding ACV synthetase, isopenicillin N synthase, acyltransferase, phosphoglycerate kinase or gene Y. Transcriptional terminators can be obtained from the same genes as well.
  • a process for the fermentative production of 7-ACA or a derivative thereof comprising the use of a P. chrysogenum strain transformed with expression constructs wherein the coding sequence of the gene encoding expandase, hydroxylase and/or acetyltransferase activity is fused to a promoter sequence which is heterologous for said coding sequence.
  • Said heterologous promoter sequence for example is the IPNS (pcbC) promoter from P. chrysogenum.
  • exact fusions between a promoter sequence of choice and the start codon of the coding sequence encoding expandase, hydroxylase and/or acetyltransferase activity are conveniently obtained using PCR technology.
  • Transformation of P. chrysogenum host cells can, in general, be achieved by different means of DNA delivery, like PEG-Ca mediated protoplast uptake, electroporation or particle gun techniques, and subsequent selection of transformants.
  • PEG-Ca mediated protoplast uptake like PEG-Ca mediated protoplast uptake, electroporation or particle gun techniques, and subsequent selection of transformants.
  • Van den Hondel en Punt, Gene and Transfer and Vector Development for Filamentous Fungi in: Applied Molecular Genetics of Fungi (Peberdy, Laten, Ogden, Bennett, eds.), Cambridge University Press (1 991 ).
  • the application of dominant and non-dominant selection markers has been described (Van den Hondel, supra). Selection markers of both homologous (P. chrysogenum derived) and heterologous (non- P. chrysogenum derived) origin have been described (Gouka e_t aj., J. Biotechnol. 20
  • a suitable side chain precursor is defined as an N-acyl side chain precursor leading to an N-acyl side chain of the fermentatively produced cephem compound, said N-acyl side chain being amenable to simple chemical or enzymatical removal.
  • a suitable side chain precursor is a dicarboxylic acid, more particularly a dicarboxylic acid according to formula (1 )
  • n is an even number of at least 2
  • X is (CH 2 ) p -A-(CH 2 ) q , wherein p and q each individually are 0, 1 , 2, 3 or 4, and
  • Suitable side chain precursors according to Formula (1 ) are adipic acid, 3'-carboxymethylthiopropionic acid (WO 95/04148), 3, 3'- thiodipropionic acid (WO 95/041 49) or the side chain precursors as provided in WO 98/48034 or WO 98/48035.
  • Preferred side chain precursors are adipic acid or trans- ⁇ -hydromuconic acid.
  • the N-acylated 7-ACA compound for instance adipoyl-7-ACA, as obtained by fermentation in the presence of a suitable acyl side chain precursor, for instance adipic acid, may efficiently be recovered from the fermentation medium through conventional recovery technology, for instance a simple solvent extraction process as follows:
  • the broth is filtered and an organic solvent immiscible with water is added to the filtrate.
  • the pH is adjusted in order to extract the cephalosporin from the aqueous layer.
  • the pH range has to be lower than 4.5; preferably between 4 and 1 , more preferably between 2 and 1 . In this way the cephalosporin is separated from many other impurities present in the fermentation broth.
  • a small volume of organic solvent is used, giving a more concentrated solution of the cephalosporin, so achieving reduction of the volumetric flow rates.
  • a second possibility is whole broth extraction at a pH of 4 or lower.
  • the broth is extracted at a pH between 4 and 1 with an organic solvent immiscible with water.
  • Suitable solvents are, for instance, butyl acetate, ethyl acetate, methyl isobutyl ketone, alcohols like butanol, etc..
  • cephalosporin is back extracted with water at a pH between 4 and 10, preferably between 6 and 9. Again the final volume can be reduced.
  • the recovery can be carried out at temperatures between 0 and 50 °C, and preferably at temperatures between 0 and 1 0 °C.
  • the N-acylated cephalosporin derivatives produced by the process of the invention can conveniently be used as an intermediate for the chemical synthesis of semisynthetic cephalosporins, since the 7-amino group is adequately protected by presence of an appropriate acyl side chain.
  • the aqueous N-acylated cephalosporin solution thus obtained is treated with a suitable enzyme in order to remove the N-acyl, e.g. the adipoyl, side chain and obtain the desired 7-ACA.
  • a suitable enzyme in order to remove the N-acyl, e.g. the adipoyl, side chain and obtain the desired 7-ACA.
  • an immobilised enzyme is used, in order to be able to use the enzyme repeatedly.
  • the methodology for the preparation of such particles and the immobilisation of the enzymes have been described extensively in EP 0 222 462.
  • the pH of the aqueous solution has a value of, for example pH 4 to pH 9, at which the degradation reaction of cephalosporin is minimised and the desired conversion with the enzyme is optimised.
  • the enzyme is added to the aqueous cephalosporin solution while maintaining the pH at the appropriate level by, for instance, adding an inorganic base, such as a potassium hydroxide solution, or applying a cation exchange resin.
  • an inorganic base such as a potassium hydroxide solution
  • a cation exchange resin When the reaction is completed the immobilised enzyme is removed by filtration.
  • Another possibility is the application of the immobilised enzyme in a fixed or fluidised bed column, or using the enzyme in solution and removing the products by membrane filtration. Subsequently, the pH of the aqueous solution is adjusted to a value between 2 and 5, preferably between 3 and 4. The crystalline 7-ACA is then filtered off.
  • Suitable enzymes are, for instance, derived from a Pseudomonas SY77 micro-organism having a mutation in one or more of the positions 62, 1 77, 1 78 and 1 79. Also enzymes from other Pseudomonas micro-organisms, preferably Pseudomonas SE83, optionally having a mutation in one or more of the positions corresponding to the 62, 1 77, 1 78 and 1 79 positions in Pseudomonas SY77, may be used.
  • the deacylation can also be carried out chemically as known in the art, for instance, via the formation of an iminochloride side chain, by adding phosphorus pentachloride at a temperature of lower than 10 °C and subsequently an alcohol like isobutanol at ambient temperatures or lower.
  • the aqueous solution containing the N-acylated 7-ACA derivative or the 7-ACA as obtained after deacylation may be treated by a suitable acetylating agent to convert any (acyl)-7-ADAC which may be present in said aqueous solution to the corresponding (acyl)-7- ACA derivative.
  • Said acetylation for instance can be done using acetic anhydride, for instance by the method as disclosed in US 5,221 ,739, or using a suitable lipase or esterase, for instance as disclosed in EP 667 396.
  • the 7-ACA compound as obtained by the process of the invention is used as a starting compound in the preparation of a wide variety of cephalosporin antibiotics, end products as well as intermediates thereto.
  • the free amino group of 7-ACA for instance may be acylated with any suitable side chain, using commonly known chemical or enzymatical coupling methods, resulting in an N-acylated 7-ACA derivative.
  • substitutions at the 3' position may occur.
  • cephalosporin compounds are cefotaxime, cefazolin, ceftriaxone, cefuroxime, cefprozil, ceftazidime and cefaclor.
  • plCG ⁇ A, plCG 2 WA and plCG 3 WA for acetyltransferase expression In Penicillium chrysogenum
  • the desacetylcephalosporin C acetyltransferase (cefG) expression cassette plCG.,WA which contains the wild type Acremonium chrysogenum cefG gene including the Penicillium chrysogenum pcbC promoter and penDE terminator, was constructed as described below.
  • the N-terminal part of the cefG gene i.e. starting at the first ATG of the ORF, was derived from A. chrysogenum chromosomal DNA in a PCR reaction using primers #1 and #2 (SEQ ID NO 1 and 2, respectively) .
  • the C-terminal part of the cefG gene was derived from the same template in a PCR reaction using primers #3 and #4 (SEQ ID NO 3 and 4, respectively) . After a fusion PCR using primers #1 and #4 and the above fragments as template, a complete cefG gene (further indicated herein as the cefG ⁇ gene) was generated in which the internal Sfi ⁇ and Hind ⁇ sites were deleted and a novel Nsi ⁇ site was created.
  • the first part of the pcbC promoter was PCR-amplified using primers #5 and #6 (SEQ ID NO 5 and 6, respectively) and, after a fusion PCR using primers #5 and #4, introduced directly in front of the cefG gene.
  • primers #5 and #6 SEQ ID NO 5 and 6, respectively
  • a fusion PCR using primers #5 and #4 introduced directly in front of the cefG gene.
  • PstMNsi ⁇ a 1 592 bp fragment was Iigated to a 4.3 kb Pst ⁇ INsi vector fragment of plSEWA-N (vector previously described in WO98/46772) to yield the Penicillium transformation vector plCG ⁇ A .
  • the N-terminal part of the cefG 2 gene i.e.
  • plCG 3 WA wherein the cefG gene starts at the third ATG
  • primers #5/#1 0 SEQ ID NO 5/1 0, respectively
  • #1 1 /#9 SEQ ID NO 1 1 /9, respectively
  • the cefG 2 /cefG 3 fusion fragments were ligated to a Pst ⁇ INco ⁇ vector fragment of pICG ⁇ WA yielding the Penicillium transformation vectors plCG 2 WA and plCG 3 WA.
  • the P. chrysogenum strain which was used has previously been transformed with an expression construct comprising the bifunctional expandase/hydroxylase coding sequence (cefEF) from A. chrysogenum under regulatory control of the P. chrysogenum pcbC promoter and pe ⁇ DE terminator.
  • cefEF bifunctional expandase/hydroxylase coding sequence
  • the fragments were co-transformed with amdS (EP 635 574), which enables P. chrysogenum transformants to grow on selection medium containing acetamide as sole nitrogen source. Transformants were purified by repeated cultivation on selective medium. Single stable colonies were used for further screening on the presence of the cefG gene by PCR. CefG positive colonies were used for further screening of expression of cefG by measuring the capacity of the transformants to produce adipoyl-7-ACA.
  • transformants were inoculated in liquid medium as described in WO 95/04149, supplemented with 0.5-3 mg/ml sodium adipate as a side chain precursor for production tests. Filtrates of well grown cultures were analysed by HPLC and NMR for adipoyl-7-ACA production.
  • Table 1 clearly show an increased adipoyi-7-ACA production for transformants comprising cefG starting at the second ATG of the ORF (indicated as "ATG2”), as compared to the transformants comprising cefG starting at the first ATG (indicated as "ATG 1 ”) or the third ATG (indicated as "ATG3").

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La présente invention traite d'un procédé de production de 7-ACA ou d'un dérivé de ce dernier. Ce procédé comprend les étapes consistant à faire fermenter une souche de P.chrysogenum transformée par un produit de construction d'expression comprenant une séquence de nucléotides codant l'activité de l'expandase, l'hydroxylase et l'acétyltransférase en présence d'un précurseur de chaîne latérale d'acyle approprié, ou d'un sel ou un ester de ce dernier, de manière à produire un composé 7-ACA N-acylé. Ce procédé consiste ensuite à N-désacyler le composé 7-ACA N-acylé ainsi obtenu et éventuellement, à acyler le groupe amino libre et/ou substituer le groupe 3'acétate par une chaîne latérale permettant de former un antibiotique céphalosporine. Ce procédé se caractérise en ce que la séquence de nucléotides codant l'acétyltransférase est dérivée de Acremonium chrysogenum et commence au niveau du deuxième ATG de la trame de lecture ouverture dans ladite séquence de nucléotides.
EP99964657A 1998-12-22 1999-12-21 Production in vivo amelioree de cephalosporines Withdrawn EP1141372A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP99964657A EP1141372A2 (fr) 1998-12-22 1999-12-21 Production in vivo amelioree de cephalosporines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP98204469 1998-12-22
EP98204469 1998-12-22
PCT/EP1999/010292 WO2000037671A2 (fr) 1998-12-22 1999-12-21 Production in vivo amelioree de cephalosporines
EP99964657A EP1141372A2 (fr) 1998-12-22 1999-12-21 Production in vivo amelioree de cephalosporines

Publications (1)

Publication Number Publication Date
EP1141372A2 true EP1141372A2 (fr) 2001-10-10

Family

ID=8234568

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99964657A Withdrawn EP1141372A2 (fr) 1998-12-22 1999-12-21 Production in vivo amelioree de cephalosporines

Country Status (7)

Country Link
EP (1) EP1141372A2 (fr)
JP (1) JP2002533092A (fr)
KR (1) KR20010089672A (fr)
CN (1) CN1331751A (fr)
AU (1) AU3042600A (fr)
HK (1) HK1041610A1 (fr)
WO (1) WO2000037671A2 (fr)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004113508A1 (fr) * 2003-06-20 2004-12-29 Dsm Ip Assets B.V. Production d'intermediaires de la cephalosporine dans penicillium chrysogenum
US8735112B2 (en) 2007-11-20 2014-05-27 Dsm Ip Assets B.V. Dicarboxylic acid production in a recombinant yeast
EP2222854A1 (fr) 2007-11-20 2010-09-01 DSM IP Assets B.V. Production d'acide dicarboxylique dans un champignon filamenteux
US9340804B2 (en) 2007-11-20 2016-05-17 Dsm Ip Assets B.V. Dicarboxylic acid production in eukaryotes
CN101555463B (zh) * 2008-04-08 2012-05-30 中国科学院上海生命科学研究院湖州工业生物技术中心 表达头孢菌素脱乙酰酶的重组大肠杆菌菌株及其构建方法
EP2116136A1 (fr) 2008-05-08 2009-11-11 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Nouvelles phytases
EP2408907B8 (fr) 2009-03-17 2018-04-18 Dutch DNA Biotech B.V. Utilisation des protéines actives sur cellulose et lignocellulose
WO2010118932A1 (fr) 2009-04-15 2010-10-21 Dsm Ip Assets B.V. Procédé de production d'acide dicarboxylique
UA108853C2 (uk) 2009-07-10 2015-06-25 Спосіб ферментації галактози
CA2794817C (fr) 2010-04-21 2019-03-12 Dsm Ip Assets B.V. Cellule adaptee pour la fermentation d'une composition de sucre melange
EP2388331A1 (fr) 2010-05-21 2011-11-23 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Promoteur constitutif
CA2813513A1 (fr) 2010-10-13 2012-04-19 Dsm Ip Assets B.V. Polypeptides avec activite de permease
CA2833312A1 (fr) 2011-04-22 2012-10-26 Dsm Ip Assets B.V. Cellule de levure pouvant convertir des sucres comprenant l'arabinose et le xylose
AR087423A1 (es) 2011-08-04 2014-03-19 Dsm Ip Assets Bv Celula capaz de fermentar azucares pentosas
EP2554668A1 (fr) 2011-08-04 2013-02-06 DSM IP Assets B.V. Cellule de fermentation de sucre de pentose
EA201400836A8 (ru) 2012-01-23 2016-03-31 ДСМ АйПи АССЕТС Б.В. Получение дитерпена
PL2909305T3 (pl) 2012-10-16 2019-06-28 Dsm Ip Assets B.V. Komórki o ulepszonej konwersji pentozy
EP2772545A1 (fr) 2013-03-01 2014-09-03 Nederlandse Organisatie voor toegepast -natuurwetenschappelijk onderzoek TNO Protéines d'amidon actives
EP2981610A1 (fr) 2013-04-05 2016-02-10 Université du Luxembourg Production biotechnologique d'acide itaconique
WO2014178717A1 (fr) 2013-05-02 2014-11-06 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Nouvelle voie de l'acide organique
US10689681B2 (en) 2013-05-31 2020-06-23 Dsm Ip Assets B.V. Microorganisms for diterpene production
WO2015007748A1 (fr) 2013-07-15 2015-01-22 Dsm Ip Assets B.V. Production de diterpène
EP3536697A1 (fr) 2013-07-31 2019-09-11 DSM IP Assets B.V. Récupération de glycosides de stéviol
WO2016131818A1 (fr) 2015-02-16 2016-08-25 Dsm Ip Assets B.V. Processus de production d'acide itaconique en conditions anaérobies
CA3255837A1 (en) 2015-03-16 2025-10-30 Dsm Ip Assets B.V. Udp-glycosyltransferases
US20180057850A1 (en) 2015-03-23 2018-03-01 Dsm Ip Assets B.V. Udp-glycosyltransferases from solanum lycopersicum
CN113683712B (zh) 2015-04-03 2022-10-21 帝斯曼知识产权资产管理有限公司 甜菊醇糖苷
WO2016170045A1 (fr) 2015-04-21 2016-10-27 Dsm Ip Assets B.V. Géranylgéranyle pyrophosphate synthase
ES2755680T3 (es) 2015-05-22 2020-04-23 Dsm Ip Assets Bv Célula de levadura que consume acetato
BR112018000550B1 (pt) 2015-07-10 2022-05-10 Dsm Ip Assets B.V. Método para preparar uma composição de glicosídeo de esteviol
US20180230505A1 (en) 2015-08-13 2018-08-16 Dsm Ip Assets B.V. Steviol glycoside transport
WO2017050652A1 (fr) 2015-09-25 2017-03-30 Dsm Ip Assets B.V. Asparaginase
WO2017060318A2 (fr) 2015-10-05 2017-04-13 Dsm Ip Assets B.V. Hydroxylases de l'acide kaurénoïque
MY186400A (en) 2015-10-06 2021-07-22 Dsm Ip Assets Bv Eukaryotic cell with increased production of fermentation product
EP3397759A2 (fr) 2015-12-30 2018-11-07 DSM IP Assets B.V. Hydrolyse enzymatique partielle des triacylglycérols
CA3009871A1 (fr) 2015-12-30 2017-07-06 Dsm Ip Assets B.V. Hydrolyse enzymatique partielle des triacylglycerols
WO2017167848A1 (fr) 2016-03-31 2017-10-05 Dsm Ip Assets B.V. Composition enzymatique et préparation d'un produit laitier ayant des propriétés améliorées
EP3435772A1 (fr) 2016-03-31 2019-02-06 DSM IP Assets B.V. Composition enzymatique et préparation d'un produit laitier aux propriétés améliorées
WO2017167847A1 (fr) 2016-03-31 2017-10-05 Dsm Ip Assets B.V. Production de lait à faible teneur en lactose
WO2017216136A1 (fr) 2016-06-14 2017-12-21 Dsm Ip Assets B.V. Cellule de levure recombinée
US10787649B2 (en) 2016-07-13 2020-09-29 Dsm Ip Assets B.V. Malate dehyrogenases
BR112019002417B1 (pt) 2016-08-09 2023-05-02 Dsm Ip Assets B.V. Cristalização de glicosídeos de esteviol
BR112019002432A2 (pt) 2016-08-09 2019-06-04 Dsm Ip Assets Bv cristalização de glicosídeos de esteviol
KR101808192B1 (ko) * 2016-08-26 2018-01-18 아미코젠주식회사 7-아미노세팔로스포란산의 고농도 생산 재조합 아크레모니움 크리소제눔 균주의 제조방법 및 이 방법으로 제조된 균주
WO2018037123A1 (fr) 2016-08-26 2018-03-01 Lesaffre Et Compagnie Production améliorée d'acide itaconique
WO2018073107A1 (fr) 2016-10-19 2018-04-26 Dsm Ip Assets B.V. Cellule eucaryote comprenant de la xylose isomérase
WO2018078014A1 (fr) 2016-10-27 2018-05-03 Dsm Ip Assets B.V. Géranylgéranyl-pyrophosphate synthases
US11104886B2 (en) 2016-12-08 2021-08-31 Dsm Ip Assets B.V. Kaurenoic acid hydroxylases
US10918113B2 (en) 2016-12-21 2021-02-16 Dsm Ip Assets B.V. Lipolytic enzyme variants
WO2018114940A1 (fr) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Variants d'enzyme lipolytique
WO2018114938A1 (fr) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Variants d'enzyme lipolytique
WO2018114912A1 (fr) 2016-12-21 2018-06-28 Dsm Ip Assets B.V. Variants d'enzyme lipolytique
WO2018114995A1 (fr) 2016-12-22 2018-06-28 Dsm Ip Assets B.V. Procédés de fermentation pour la production de glycosides de stéviol
EP3638770B1 (fr) 2017-06-13 2023-01-18 DSM IP Assets B.V. Cellule de levure de recombinaison
EP3645714B1 (fr) 2017-06-27 2022-08-31 DSM IP Assets B.V. Glycosyltransférases udp
EP3688177A1 (fr) 2017-09-26 2020-08-05 DSM IP Assets B.V. Souche consommatrice d'acide acétique
EP3533878A1 (fr) 2018-02-28 2019-09-04 Dutch DNA Biotech B.V. Procédé de production d'acide 2-hydroxy-2-méthylsuccinique en utilisant d'aspergillus
BR112020025589A2 (pt) 2018-06-19 2021-03-23 Dsm Ip Assets B.V. variantes de enzima lipolítica
WO2022084482A1 (fr) 2020-10-22 2022-04-28 Dsm Ip Assets B.V. Microorganismes pour la production de diterpènes
AU2022297881A1 (en) 2021-06-24 2024-01-18 Fonterra Co-Operative Group Limited Recombinant beta-lactoglobulin
US20250283121A1 (en) 2021-07-12 2025-09-11 Danisco Us Inc. Recombinant yeast cell
CN117916381A (zh) 2021-07-12 2024-04-19 丹尼斯科美国公司 重组酵母细胞
CN117940570A (zh) 2021-07-12 2024-04-26 丹尼斯科美国公司 重组酵母细胞
WO2023285280A1 (fr) 2021-07-12 2023-01-19 Dsm Ip Assets B.V. Cellule de levure recombinante
EP4370690A1 (fr) 2021-07-12 2024-05-22 Danisco Us Inc Cellule de levure recombinée
MX2024005281A (es) 2021-11-04 2024-05-17 Danisco Us Inc Celula de levadura recombinante.
US20240425888A1 (en) 2021-11-04 2024-12-26 Danisco Us Inc. Process for the production of ethanol and recombinant yeast cell
US20240409965A1 (en) 2021-11-04 2024-12-12 Danisco Us Inc. Variant polypeptide and recombinant yeast cell
AU2022388727A1 (en) 2021-11-09 2024-05-16 Amgen Inc. Production of therapeutic proteins
EP4525626A1 (fr) 2022-05-16 2025-03-26 DSM IP Assets B.V. Variants d'enzymes lipolytiques
EP4698673A1 (fr) 2023-04-20 2026-02-25 DSM IP Assets B.V. Souches et procédés de production de mogrosides
EP4743572A1 (fr) 2023-07-11 2026-05-20 DSM IP Assets B.V. Arginine déiminase protéique
WO2025144785A2 (fr) 2023-12-28 2025-07-03 Dsm Ip Assets B.V. Cellules et procédés de production de composés glycosylés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK280569B6 (sk) * 1991-10-15 2000-03-13 Gist-Brocades B.V. Biologický spôsob výroby kyseliny7-aminodeacetylce
EP0566897A3 (en) * 1992-04-07 1994-07-06 Hoechst Ag The complete gene (cefg) encoding the acetyl-coa: deacetylcephalosporin c acetyltransferase of cephalosporium acremonium, its isolation and use
WO1995004148A1 (fr) * 1993-07-30 1995-02-09 Gist-Brocades B.V. Procede de production efficace de 7-adca par l'intermediaire du 2-(carboxyethylthio)acetyl-7-adca et du 3-(carboxymethylthio)propionyl-7-adca
CN1087780C (zh) * 1993-07-30 2002-07-17 吉斯特·布罗卡迪斯公司 通过3－(羧乙硫基)丙酰－7－adca有效生产7－adca的方法
RU2208643C2 (ru) * 1997-04-22 2003-07-20 Дсм Гист Б.В. Способ получения n-деацилированного цефалоспорина

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0037671A2 *

Also Published As

Publication number Publication date
AU3042600A (en) 2000-07-12
WO2000037671A2 (fr) 2000-06-29
CN1331751A (zh) 2002-01-16
KR20010089672A (ko) 2001-10-08
WO2000037671A3 (fr) 2000-09-14
JP2002533092A (ja) 2002-10-08
HK1041610A1 (zh) 2002-07-12

Similar Documents

Publication Publication Date Title
WO2000037671A2 (fr) Production in vivo amelioree de cephalosporines
RU2230790C2 (ru) Способ расширения 5-членного кольца соединения бета-лактама до 6-членного цефема
KR100336174B1 (ko) 2-(카르복시에틸티오)아세틸-7-adca및3-(카르복시메틸티오)프로피오닐-7-adca를경유하여7-adca를제조하는효율적인방법
US6518039B2 (en) Process for the fermentative production of deacylated cephalosporins
EP0711348B1 (fr) Procede de production efficace de 7-adca par l'intermediaire du 3-(carboxyethylthio)propionyl-7-adca
HU219370B (en) Novel bioprocesses for preparing 7-aca and 7-adac
US5731165A (en) Process for the production of 7-ADCA via expandase activity on penicillin G
EP0915988B1 (fr) Procede de production fermentative de cephalosporines desacylees
WO1998002551A2 (fr) Procede ameliore de production de cephalosporines d'adipoyle
US6368820B1 (en) Process for the preparation of cephalosporins using acremonium chrysogenum
US6020151A (en) Process for the production of 7-ADCA via expandase activity on penicillin G
EP0716698B1 (fr) Procédé de production efficace de 7-ADCA par l'intermédiaire du 2-(carboxyethylthio)acetyl-7-ADCA et du 3-(carboxymethylthio)propionyl-7-ADCA
HK1036480A (en) Improved in vivo production of cephalosporins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010613

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20010613;LT PAYMENT 20010613;LV PAYMENT 20010613;MK PAYMENT 20010613;RO PAYMENT 20010613;SI PAYMENT 20010613

17Q First examination report despatched

Effective date: 20021030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030311